[go: up one dir, main page]

MX2008011872A - Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. - Google Patents

Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.

Info

Publication number
MX2008011872A
MX2008011872A MX2008011872A MX2008011872A MX2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A MX 2008011872 A MX2008011872 A MX 2008011872A
Authority
MX
Mexico
Prior art keywords
hypertension
treatment
lowering lipids
thiazolidinedione analogues
thiazolidinedione
Prior art date
Application number
MX2008011872A
Other languages
English (en)
Inventor
Rolf F Kletzien
Gerard R Colca
Original Assignee
Metabolic Solutions Dev Compan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Compan filed Critical Metabolic Solutions Dev Compan
Publication of MX2008011872A publication Critical patent/MX2008011872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con análogos de tiazolidinediona que son útiles para tratar la hipertensión.
MX2008011872A 2006-03-16 2007-03-14 Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos. MX2008011872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78278706P 2006-03-16 2006-03-16
PCT/US2007/006385 WO2007109037A2 (en) 2006-03-16 2007-03-14 Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids

Publications (1)

Publication Number Publication Date
MX2008011872A true MX2008011872A (es) 2009-02-10

Family

ID=38433001

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011872A MX2008011872A (es) 2006-03-16 2007-03-14 Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.

Country Status (11)

Country Link
US (1) US8629159B2 (es)
EP (1) EP2001469B1 (es)
JP (2) JP5149271B2 (es)
CN (1) CN101454006B (es)
AU (1) AU2007227594B2 (es)
CA (1) CA2646149A1 (es)
ES (1) ES2388555T3 (es)
MX (1) MX2008011872A (es)
NZ (1) NZ571870A (es)
PL (1) PL2001469T3 (es)
WO (1) WO2007109037A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571872A (en) * 2006-03-16 2011-05-27 Metabolic Solutions Dev Co Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
CA2646149A1 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
EP2001468B1 (en) * 2006-03-16 2012-10-31 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
NZ583889A (en) 2007-09-14 2012-01-12 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
CA2783468C (en) 2009-12-15 2018-10-09 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
ES2617704T3 (es) * 2009-12-15 2017-06-19 Octeta Therapeutics, Llc Tiazolidindionas ahorradoras de PPAR y combinaciones para el tratamiento de enfermedades neurodegenerativas
US20130211095A1 (en) * 2010-04-19 2013-08-15 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
EP2560956B1 (en) * 2010-04-19 2016-10-26 Octeta Therapeutics, LLC Novel synthesis for thiazolidinedione compounds
RU2593370C2 (ru) 2010-08-10 2016-08-10 Октета Терапьютикс, ЭлЭлСи Новый способ синтеза соединений тиазолидиндиона
CN102370984B (zh) * 2010-08-18 2015-04-08 天津金耀集团有限公司 以依普利酮和糖皮质激素为活性成分的吸入药物组合物
DK3024816T3 (da) 2013-07-22 2020-08-31 Metabolic Solutions Dev Co Llc Ppar-sparende forbindelser til behandling af metaboliske sygdomme
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension
PL4101454T3 (pl) 2017-01-25 2024-07-29 The George Institute for Global Health Kompozycje do stosowania w leczeniu nadciśnienia
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1985004170A1 (fr) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, leur procede de preparation et compositions medicinales les contenant
WO1986002073A1 (fr) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
AU1743292A (en) * 1991-04-11 1992-11-17 Takeda Chemical Industries Ltd. Thiazolidinedione derivatives, production and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
ATE355286T1 (de) 2001-04-26 2006-03-15 Zentiva As Verfahren zur herstellung von pioglitazone als antidiabetisches mitttel
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
ITFI20030058A1 (it) 2003-03-06 2004-09-07 Univ Firenze Formulazioni farmaceutiche contenenti tiazolidinedioni
NZ571872A (en) 2006-03-16 2011-05-27 Metabolic Solutions Dev Co Combination therapies of thiazolidinedione analogues and glucocorticoid agonists
CA2646149A1 (en) 2006-03-16 2007-09-27 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
EP2001468B1 (en) 2006-03-16 2012-10-31 Metabolic Solutions Development Company LLC Thiazolidinedione analogues
NZ583889A (en) 2007-09-14 2012-01-12 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension

Also Published As

Publication number Publication date
JP5149271B2 (ja) 2013-02-20
WO2007109037A3 (en) 2007-11-08
EP2001469A2 (en) 2008-12-17
AU2007227594A1 (en) 2007-09-27
AU2007227594B2 (en) 2012-11-15
EP2001469B1 (en) 2012-05-23
CA2646149A1 (en) 2007-09-27
JP2012251001A (ja) 2012-12-20
JP2009530286A (ja) 2009-08-27
PL2001469T3 (pl) 2012-10-31
WO2007109037A2 (en) 2007-09-27
NZ571870A (en) 2011-07-29
CN101454006B (zh) 2012-12-26
US20090137638A1 (en) 2009-05-28
ES2388555T3 (es) 2012-10-16
US8629159B2 (en) 2014-01-14
CN101454006A (zh) 2009-06-10

Similar Documents

Publication Publication Date Title
MX2008011872A (es) Analogos de tiazolidinediona para el tratamiento de la hipertension y para disminuir lipidos.
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2011022489A3 (en) (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
WO2007092622A3 (en) Compositions and methods for treating bone
IL197080A0 (en) Pyrimidone compounds as gsk-3 inhibitors
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MY152282A (en) Compositions and methods for use antibodies against sclerostin
MX2010007490A (es) Preparacion de derivados de sulfamida.
ZA200900388B (en) Compositions and methods for the treatment of mucositis
SG155163A1 (en) Pharmacokinetically improved compounds
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA200900021A1 (ru) Пептидные соединения для лечения рефрактерного эпилептического статуса
IN2012DN02624A (es)
PH12012500916B1 (en) Treatments for gastrointestinal disorders
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
WO2007109088A3 (en) Combinationtherapies of thiazolidinedione analogues and glucocorticoid agonists

Legal Events

Date Code Title Description
FG Grant or registration